Last update 23 Jan 2025
Pulmagen Therapeutics LLP

Pulmagen Therapeutics LLP

Private Company|
2010|
United Kingdom
|
www.pulmagen.com

Overview

Tags

Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
RORG(Nuclear receptor ROR-gamma)1

Related

3
Drugs associated with Pulmagen Therapeutics LLP
Pexopiprant
Target
CRTH2
Mechanism
CRTH2 antagonists
Active Org.
Gossamer Bio, Inc.Gossamer Bio, Inc.
Originator Org.
Pulmagen Therapeutics LLPPulmagen Therapeutics LLP
Active Indication
Inflammation
Inactive Indication
Allergic asthma [+3]
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
GNE-0946
Target
RORG
Mechanism
RORG inverse agonists
Active Org.
Pulmagen Therapeutics (Asthma) Ltd. [+1]
Originator Org.
Genentech, Inc.Genentech, Inc. [+1]
Active Indication
Autoimmune Diseases
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
ADC-7405
Target
CRTH2 x H-PGDS
Mechanism
CRTH2 antagonists [+1]
Active Org.-
Originator Org.
Pulmagen Therapeutics LLPPulmagen Therapeutics LLP
Active Indication-
Inactive Indication
Asthma
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
5
Clinical Trials associated with Pulmagen Therapeutics LLP
NCT01730027
/ CompletedPhase 2
A Randomised, Double Blind, Placebo-Controlled, Multi-Centre, Parallel Group Study to Evaluate the Efficacy and Safety of ADC3680 Administered Once Daily as an Add-On Therapy to Inhaled Corticosteroids and When Co-Administered With Montelukast in Subjects With Inadequately-Controlled Asthma.
EUCTR2011-002816-97-GB
/ Not yet recruitingNot Applicable
A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects with Partly Controlled Atopic Asthma
NCT01448954
/ CompletedPhase 2
A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
100 Clinical Results associated with Pulmagen Therapeutics LLP
Login to view more data
0 Patents (Medical) associated with Pulmagen Therapeutics LLP
Login to view more data
100 Deals associated with Pulmagen Therapeutics LLP
Login to view more data
100 Translational Medicine associated with Pulmagen Therapeutics LLP
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
2
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
GNE-0946
 ( RORG )		Autoimmune Diseases
More
Preclinical
Pexopiprant
 ( CRTH2 )		-
Pending
ADC-7405
 ( CRTH2 x H-PGDS )		Asthma
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free